{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T14:01:56Z","timestamp":1772028116173,"version":"3.50.1"},"reference-count":109,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100010661","name":"Horizon 2020","doi-asserted-by":"publisher","award":["666918"],"award-info":[{"award-number":["666918"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R025134\/1"],"award-info":[{"award-number":["MR\/R025134\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R015325\/1"],"award-info":[{"award-number":["MR\/R015325\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/S009434\/1"],"award-info":[{"award-number":["MR\/S009434\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/N026101\/1"],"award-info":[{"award-number":["MR\/N026101\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/S036784\/1"],"award-info":[{"award-number":["MR\/S036784\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000317","name":"Action Medical Research","doi-asserted-by":"publisher","award":["GN2485"],"award-info":[{"award-number":["GN2485"]}],"id":[{"id":"10.13039\/501100000317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"UCL","doi-asserted-by":"publisher","award":["204841\/Z\/16\/Z"],"award-info":[{"award-number":["204841\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000765","name":"UCL","doi-asserted-by":"publisher","award":["2017-T2\/BMD-5323"],"award-info":[{"award-number":["2017-T2\/BMD-5323"]}],"id":[{"id":"10.13039\/501100000765","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"MRC","doi-asserted-by":"publisher","award":["MC_U12266B"],"award-info":[{"award-number":["MC_U12266B"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.bbadis.2020.165772","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T12:04:14Z","timestamp":1585051454000},"page":"165772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Experimental gene therapies for the NCLs"],"prefix":"10.1016","volume":"1866","author":[{"given":"Wenfei","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia-Martha","family":"kleine-Holthaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saul","family":"Herranz-Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikel","family":"Aristorena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara E.","family":"Mole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin R.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahad A.","family":"Rahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2020.165772_bb0005","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002716","article-title":"Hematopoietic stem cell gene therapy for adenosine deaminase-deficient severe combined immunodeficiency leads to long-term immunological recovery and metabolic correction","volume":"3","author":"Gaspar","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbadis.2020.165772_bb0010","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.ymthe.2017.12.022","article-title":"Gene therapy for adenosine deaminase deficiency: a comprehensive evaluation of short- and medium-term safety","volume":"26","author":"Cicalese","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbadis.2020.165772_bb0015","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2016-01-688226","article-title":"Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"128","author":"Cicalese","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2020.165772_bb0020","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa0805817","article-title":"Gene therapy for immunodeficiency due to adenosine deaminase deficiency","volume":"360","author":"Aiuti","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2020.165772_bb0025","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1089\/hum.2017.175","article-title":"Twenty-five years of gene therapy for ADA-SCID: from bubble babies to an approved drug","volume":"28","author":"Ferrua","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bbadis.2020.165772_bb0030","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jama.2015.3253","article-title":"Outcomes following gene therapy in patients with severe Wiskott-Aldrich syndrome","volume":"313","author":"Abina","year":"2015","journal-title":"Jama"},{"key":"10.1016\/j.bbadis.2020.165772_bb0035","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/S2352-3026(19)30021-3","article-title":"Lentiviral haemopoietic stem\/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1\/2 clinical study","volume":"6","author":"Ferrua","year":"2019","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.bbadis.2020.165772_bb0040","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3007280","article-title":"Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity","volume":"6","author":"Braun","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbadis.2020.165772_bb0045","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233151","article-title":"Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome","volume":"341","author":"Aiuti","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2020.165772_bb0050","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1815408","article-title":"Lentiviral gene therapy combined with low-dose busulfan in infants with SCID-X1","volume":"380","author":"Mamcarz","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2020.165772_bb0055","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1056\/NEJMoa1404588","article-title":"A modified gamma-retrovirus vector for X-linked severe combined immunodeficiency","volume":"371","author":"Hacein-Bey-Abina","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2020.165772_bb0060","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad8856","article-title":"Lentiviral hematopoietic stem cell gene therapy for X-linked severe combined immunodeficiency","volume":"8","author":"De Ravin","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbadis.2020.165772_bb0065","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2020.165772_bb0070","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2020.165772_bb0075","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2020.165772_bb0080","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2020.165772_bb0085","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood-2017-06-791202","article-title":"Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS","volume":"130","author":"Tawara","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbadis.2020.165772_bb0090","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.jcyt.2018.04.003","article-title":"Gene therapy for sickle cell disease: an update","volume":"20","author":"Demirci","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.bbadis.2020.165772_bb0095","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ymthe.2017.03.024","article-title":"Gene therapy for beta-hemoglobinopathies","volume":"25","author":"Cavazzana","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbadis.2020.165772_bb0100","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.hoc.2017.06.010","article-title":"Gene therapy approaches to hemoglobinopathies","volume":"31","author":"Ferrari","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.bbadis.2020.165772_bb0105","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/bmb\/ldy005","article-title":"Retinal gene therapy","volume":"126","author":"Kumaran","year":"2018","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.bbadis.2020.165772_bb0110","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1056\/NEJMoa0802268","article-title":"Effect of gene therapy on visual function in Leber\u2019s congenital amaurosis","volume":"358","author":"Bainbridge","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2020.165772_bb0115","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1089\/hum.2008.107","article-title":"Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial","volume":"19","author":"Hauswirth","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bbadis.2020.165772_bb0120","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1056\/NEJMoa0802315","article-title":"Safety and efficacy of gene transfer for Leber's congenital amaurosis","volume":"358","author":"Maguire","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2020.165772_bb0125","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.ophtha.2016.03.003","article-title":"Results at 2 years after gene therapy for RPE65-deficient Leber congenital amaurosis and severe early-childhood-onset retinal dystrophy","volume":"123","author":"Weleber","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bbadis.2020.165772_bb0130","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1089\/hum.1996.7.17-2101","article-title":"Quantitative analysis of the packaging capacity of recombinant adeno-associated virus","volume":"7","author":"Dong","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bbadis.2020.165772_bb0135","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(13)62117-0","article-title":"Retinal gene therapy in patients with choroideremia: initial findings from a phase 1\/2 clinical trial","volume":"383","author":"MacLaren","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2020.165772_bb0140","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/ppul.24203","article-title":"Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy","volume":"54","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"10.1016\/j.bbadis.2020.165772_bb0145","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.pediatrneurol.2019.06.007","article-title":"From clinical trials to clinical practice: practical considerations for gene replacement therapy in SMA type 1","volume":"100","author":"Al-Zaidy","year":"2019","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.bbadis.2020.165772_bb0150","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-dose gene-replacement therapy for spinal muscular atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbadis.2020.165772_bb0155","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau0713","article-title":"Gene therapy reduces Parkinson's disease symptoms by reorganizing functional brain connectivity","volume":"10","author":"Niethammer","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbadis.2020.165772_bb0160","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1089\/humc.2018.081","article-title":"Long-term follow-up of a phase I\/II study of ProSavin, a lentiviral vector gene therapy for Parkinson\u2019s disease","volume":"29","author":"Palfi","year":"2018","journal-title":"Hum. Gene. Ther. Clin. Dev."},{"key":"10.1016\/j.bbadis.2020.165772_bb0165","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.parkreldis.2019.07.018","article-title":"Human gene therapy approaches for the treatment of Parkinson\u2019s disease: an overview of current and completed clinical trials","volume":"66","author":"Hitti","year":"2019","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.bbadis.2020.165772_bb0170","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1172\/JCI28873","article-title":"Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice","volume":"116","author":"Biffi","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbadis.2020.165772_bb0175","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1172\/JCI200419205","article-title":"Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells","volume":"113","author":"Biffi","year":"2004","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbadis.2020.165772_bb0180","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2020.165772_bb0185","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","article-title":"Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial","volume":"388","author":"Sessa","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2020.165772_bb0190","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1684\/epd.2016.0844","article-title":"Neuronal ceroid lipofuscinoses","volume":"18","author":"Nita","year":"2016","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.bbadis.2020.165772_bb0195","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1002\/acn3.144","article-title":"Mice homozygous for c.451C>T mutation in Cln1 gene recapitulate INCL phenotype","volume":"1","author":"Bouchelion","year":"2014","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.bbadis.2020.165772_bb0200","doi-asserted-by":"crossref","first-page":"13566","DOI":"10.1073\/pnas.251485198","article-title":"Disruption of PPT1 or PPT2 causes neuronal ceroid lipofuscinosis in knockout mice","volume":"98","author":"Gupta","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2020.165772_bb0205","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.nbd.2004.08.013","article-title":"Mice with Ppt1Deltaex4 mutation replicate the INCL phenotype and show an inflammation-associated loss of interneurons","volume":"18","author":"Jalanko","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbadis.2020.165772_bb0210","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/hmg\/ddu428","article-title":"The novel Cln1(R151X) mouse model of infantile neuronal ceroid lipofuscinosis (INCL) for testing nonsense suppression therapy","volume":"24","author":"Miller","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2020.165772_bb0215","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.nbd.2004.02.010","article-title":"Regional and cellular neuropathology in the palmitoyl protein thioesterase-1 null mutant mouse model of infantile neuronal ceroid lipofuscinosis","volume":"16","author":"Bible","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbadis.2020.165772_bb0220","doi-asserted-by":"crossref","first-page":"12752","DOI":"10.1038\/srep12752","article-title":"Comprehensive functional characterization of murine infantile Batten disease including Parkinson-like behavior and dopaminergic markers","volume":"5","author":"Dearborn","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2020.165772_bb0225","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.nbd.2006.09.001","article-title":"Successive neuron loss in the thalamus and cortex in a mouse model of infantile neuronal ceroid lipofuscinosis","volume":"25","author":"Kielar","year":"2007","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbadis.2020.165772_bb0230","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.expneurol.2009.01.022","article-title":"Cerebellar pathology and motor deficits in the palmitoyl protein thioesterase 1-deficient mouse","volume":"217","author":"Macauley","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbadis.2020.165772_bb0235","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.nbd.2004.03.005","article-title":"Adeno-associated virus 2-mediated gene therapy decreases autofluorescent storage material and increases brain mass in a murine model of infantile neuronal ceroid lipofuscinosis","volume":"16","author":"Griffey","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbadis.2020.165772_bb0240","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ymthe.2005.04.018","article-title":"AAV2-mediated ocular gene therapy for infantile neuronal ceroid lipofuscinosis","volume":"12","author":"Griffey","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbadis.2020.165772_bb0245","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ymthe.2005.11.008","article-title":"CNS-directed AAV2-mediated gene therapy ameliorates functional deficits in a murine model of infantile neuronal ceroid lipofuscinosis","volume":"13","author":"Griffey","year":"2006","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbadis.2020.165772_bb0250","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.23545","article-title":"Synergistic effects of central nervous system-directed gene therapy and bone marrow transplantation in the murine model of infantile neuronal ceroid lipofuscinosis","volume":"71","author":"Macauley","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbadis.2020.165772_bb0255","doi-asserted-by":"crossref","first-page":"13077","DOI":"10.1523\/JNEUROSCI.2518-14.2014","article-title":"An anti-neuroinflammatory that targets dysregulated glia enhances the efficacy of CNS-directed gene therapy in murine infantile neuronal ceroid lipofuscinosis","volume":"34","author":"Macauley","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2020.165772_bb0260","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s10545-011-9446-x","article-title":"Combination small molecule PPT1 mimetic and CNS-directed gene therapy as a treatment for infantile neuronal ceroid lipofuscinosis","volume":"35","author":"Roberts","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bbadis.2020.165772_bb0265","doi-asserted-by":"crossref","first-page":"E5920","DOI":"10.1073\/pnas.1701832114","article-title":"Synergistic effects of treating the spinal cord and brain in CLN1 disease","volume":"114","author":"Shyng","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbadis.2020.165772_bb0270","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/humu.22292","article-title":"Autosomal recessive spinocerebellar ataxia 7 (SCAR7) is caused by variants in TPP1, the gene involved in classic late-infantile neuronal ceroid lipofuscinosis 2 disease (CLN2 disease)","volume":"34","author":"Sun","year":"2013","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bbadis.2020.165772_bb0275","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1038\/sj.mt.6300249","article-title":"Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease","volume":"15","author":"Cabrera-Salazar","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbadis.2020.165772_bb0280","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1523\/JNEUROSCI.2676-05.2006","article-title":"Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis","volume":"26","author":"Passini","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2020.165772_bb0285","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.mt.6300049","article-title":"Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector","volume":"15","author":"Sondhi","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbadis.2020.165772_bb0290","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.expneurol.2008.04.022","article-title":"Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis","volume":"213","author":"Sondhi","year":"2008","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbadis.2020.165772_bb0295","doi-asserted-by":"crossref","first-page":"9117","DOI":"10.1523\/JNEUROSCI.2729-04.2004","article-title":"A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration","volume":"24","author":"Sleat","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2020.165772_bb0300","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2014.09.018","article-title":"Intra-arterial delivery of AAV vectors to the mouse brain after mannitol mediated blood brain barrier disruption","volume":"196","author":"Foley","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.bbadis.2020.165772_bb0305","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/nm.2025","article-title":"Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy","volume":"15","author":"Chen","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbadis.2020.165772_bb0310","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/gt.2017.4","article-title":"Extraneuronal pathology in a canine model of CLN2 neuronal ceroid lipofuscinosis after intracerebroventricular gene therapy that delays neurological disease progression","volume":"24","author":"Katz","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.bbadis.2020.165772_bb0315","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac6191","article-title":"AAV gene transfer delays disease onset in a TPP1-deficient canine model of the late infantile form of Batten disease","volume":"7","author":"Katz","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbadis.2020.165772_bb0320","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.exer.2016.03.023","article-title":"Intracerebroventricular gene therapy that delays neurological disease progression is associated with selective preservation of retinal ganglion cells in a canine model of CLN2 disease","volume":"146","author":"Whiting","year":"2016","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.bbadis.2020.165772_bb0325","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.exer.2016.09.003","article-title":"Intravitreal implantation of TPP1-transduced stem cells delays retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis","volume":"152","author":"Tracy","year":"2016","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.bbadis.2020.165772_bb0330","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/hum.2008.022","article-title":"Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA","volume":"19","author":"Worgall","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bbadis.2020.165772_bb0335","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/jnc.13744","article-title":"Revisiting the neuronal localization and trafficking of CLN3 in juvenile neuronal ceroid lipofuscinosis","volume":"139","author":"Oetjen","year":"2016","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bbadis.2020.165772_bb0340","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1093\/hmg\/11.22.2709","article-title":"Cln3(Deltaex7\/8) knock-in mice with the common JNCL mutation exhibit progressive neurologic disease that begins before birth","volume":"11","author":"Cotman","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2020.165772_bb0345","doi-asserted-by":"crossref","first-page":"9826","DOI":"10.1523\/JNEUROSCI.1710-07.2007","article-title":"A knock-in reporter model of Batten disease","volume":"27","author":"Eliason","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2020.165772_bb0350","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1006\/mgme.1999.2828","article-title":"A murine model for juvenile NCL: gene targeting of mouse Cln3","volume":"66","author":"Greene","year":"1999","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bbadis.2020.165772_bb0355","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/(SICI)1097-4547(19990815)57:4<551::AID-JNR15>3.0.CO;2-R","article-title":"A mouse gene knockout model for juvenile ceroid-lipofuscinosis (Batten disease)","volume":"57","author":"Katz","year":"1999","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.bbadis.2020.165772_bb0360","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1089\/hum.2012.253","article-title":"Partial correction of the CNS lysosomal storage defect in a mouse model of juvenile neuronal ceroid lipofuscinosis by neonatal CNS administration of an adeno-associated virus serotype rh.10 vector expressing the human CLN3 gene","volume":"25","author":"Sondhi","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bbadis.2020.165772_bb0365","doi-asserted-by":"crossref","first-page":"9669","DOI":"10.1523\/JNEUROSCI.1635-16.2016","article-title":"Self-complementary AAV9 gene delivery partially corrects pathology associated with juvenile neuronal ceroid lipofuscinosis (CLN3)","volume":"36","author":"Bosch","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2020.165772_bb0370","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/mt.2009.71","article-title":"Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons","volume":"17","author":"Duque","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbadis.2020.165772_bb0375","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/hum.2007.093","article-title":"Neonatal intraperitoneal or intravenous injections of recombinant adeno-associated virus type 8 transduce dorsal root ganglia and lower motor neurons","volume":"19","author":"Foust","year":"2008","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bbadis.2020.165772_bb0380","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1096\/fj.11-182311","article-title":"Intravenous administration of AAV2\/9 to the fetal and neonatal mouse leads to differential targeting of CNS cell types and extensive transduction of the nervous system","volume":"25","author":"Rahim","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.bbadis.2020.165772_bb0385","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1242\/dmm.018804","article-title":"Finding the most appropriate mouse model of juvenile CLN3 (Batten) disease for therapeutic studies: the importance of genetic background and gender","volume":"8","author":"Kovacs","year":"2015","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.bbadis.2020.165772_bb0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038310","article-title":"Large-scale phenotyping of an accurate genetic mouse model of JNCL identifies novel early pathology outside the central nervous system","volume":"7","author":"Staropoli","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbadis.2020.165772_bb0395","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/dmcn.13473","article-title":"Phenotype and natural history of variant late infantile ceroid-lipofuscinosis 5","volume":"59","author":"Simonati","year":"2017","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.bbadis.2020.165772_bb0400","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.yexcr.2015.08.021","article-title":"Proteolytic processing of the neuronal ceroid lipofuscinosis related lysosomal protein CLN5","volume":"338","author":"De Silva","year":"2015","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bbadis.2020.165772_bb0405","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/hmg\/11.8.885","article-title":"Lysosomal localization of the neuronal ceroid lipofuscinosis CLN5 protein","volume":"11","author":"Isosomppi","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2020.165772_bb0410","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.yexcr.2017.04.024","article-title":"CLN5 is cleaved by members of the SPP\/SPPL family to produce a mature soluble protein","volume":"357","author":"Jules","year":"2017","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bbadis.2020.165772_bb0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074299","article-title":"The role of N-glycosylation in folding, trafficking, and functionality of lysosomal protein CLN5","volume":"8","author":"Moharir","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.bbadis.2020.165772_bb0420","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/humu.21195","article-title":"The neuronal ceroid lipofuscinosis protein CLN5: new insights into cellular maturation, transport, and consequences of mutations","volume":"31","author":"Schmiedt","year":"2010","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bbadis.2020.165772_bb0425","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ymgme.2015.04.001","article-title":"Golden Retriever dogs with neuronal ceroid lipofuscinosis have a two-base-pair deletion and frameshift in CLN5","volume":"115","author":"Gilliam","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bbadis.2020.165772_bb0430","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/jvim.13971","article-title":"Australian cattle dogs with neuronal ceroid lipofuscinosis are homozygous for a CLN5 nonsense mutation previously identified in border collies","volume":"30","author":"Kolicheski","year":"2016","journal-title":"J. Vet. Intern. Med."},{"key":"10.1016\/j.bbadis.2020.165772_bb0435","doi-asserted-by":"crossref","first-page":"383174","DOI":"10.1100\/2012\/383174","article-title":"Neuronal ceroid lipofuscinosis in Border Collie dogs in Japan: clinical and molecular epidemiological study (2000\u22122011)","volume":"2012","author":"Mizukami","year":"2012","journal-title":"ScientificWorldJournal"},{"key":"10.1016\/j.bbadis.2020.165772_bb0440","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/00480169.2002.36311","article-title":"Neuronal ceroid-lipofuscinosis in Borderdale sheep","volume":"50","author":"Jolly","year":"2002","journal-title":"N. Z. Vet. J."},{"key":"10.1016\/j.bbadis.2020.165772_bb0445","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.nbd.2007.09.006","article-title":"A new large animal model of CLN5 neuronal ceroid lipofuscinosis in Borderdale sheep is caused by a nucleotide substitution at a consensus splice site (c.571+1G>A) leading to excision of exon 3","volume":"29","author":"Frugier","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbadis.2020.165772_bb0450","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/hmg\/ddh312","article-title":"A mouse model for Finnish variant late infantile neuronal ceroid lipofuscinosis, CLN5, reveals neuropathology associated with early aging","volume":"13","author":"Kopra","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.bbadis.2020.165772_bb0455","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1016\/j.ymthe.2018.07.015","article-title":"Longitudinal in vivo monitoring of the CNS demonstrates the efficacy of gene therapy in a sheep model of CLN5 batten disease","volume":"26","author":"Mitchell","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbadis.2020.165772_bb0460","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1212\/WNL.0000000000001784","article-title":"Electroclinical spectrum of the neuronal ceroid lipofuscinoses associated with CLN6 mutations","volume":"85","author":"Canafoglia","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2020.165772_bb0465","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajhg.2011.04.004","article-title":"Kufs disease, the major adult form of neuronal ceroid lipofuscinosis, caused by mutations in CLN6","volume":"88","author":"Arsov","year":"2011","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbadis.2020.165772_bb0470","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/(SICI)1096-8628(19980526)77:4<289::AID-AJMG8>3.0.CO;2-I","article-title":"Neuronal ceroid lipofuscinosis (nclf), a new disorder of the mouse linked to chromosome 9","volume":"77","author":"Bronson","year":"1998","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.bbadis.2020.165772_bb0475","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1086\/338190","article-title":"Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse","volume":"70","author":"Gao","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbadis.2020.165772_bb0480","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1086\/338708","article-title":"The gene mutated in variant late-infantile neuronal ceroid lipofuscinosis (CLN6) and in nclf mutant mice encodes a novel predicted transmembrane protein","volume":"70","author":"Wheeler","year":"2002","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbadis.2020.165772_bb0485","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/j.ymthe.2018.02.027","article-title":"Prevention of photoreceptor cell loss in a Cln6(nclf) mouse model of Batten disease requires CLN6 gene transfer to bipolar cells","volume":"26","author":"Kleine Holthaus","year":"2018","journal-title":"Mol. Ther."},{"issue":"10","key":"10.1016\/j.bbadis.2020.165772_bb0490","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1016\/j.ymthe.2019.06.015","article-title":"Gene therapy corrects brain and behavioral pathologies in CLN6-batten disease","volume":"27","author":"Cain","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbadis.2020.165772_bb0495","series-title":"Neonatal Brain-directed Gene Therapy Rescues a Mouse Model of Neurodegenerative CLN6 Batten Disease","author":"Holthaus","year":"2019"},{"key":"10.1016\/j.bbadis.2020.165772_bb0500","doi-asserted-by":"crossref","first-page":"271","DOI":"10.2353\/ajpath.2010.091267","article-title":"CNS-expressed cathepsin D prevents lymphopenia in a murine model of congenital neuronal ceroid lipofuscinosis","volume":"177","author":"Shevtsova","year":"2010","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bbadis.2020.165772_bb0505","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1002\/j.1460-2075.1995.tb00029.x","article-title":"Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells","volume":"14","author":"Saftig","year":"1995","journal-title":"EMBO J."},{"key":"10.1016\/j.bbadis.2020.165772_bb0510","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.1523\/JNEUROSCI.20-18-06898.2000","article-title":"Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons","volume":"20","author":"Koike","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2020.165772_bb0515","doi-asserted-by":"crossref","first-page":"7526","DOI":"10.1523\/JNEUROSCI.21-19-07526.2001","article-title":"Involvement of nitric oxide released from microglia-macrophages in pathological changes of cathepsin D-deficient mice","volume":"21","author":"Nakanishi","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2020.165772_bb0520","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s00415-016-8111-6","article-title":"Early infantile neuronal ceroid lipofuscinosis (CLN10 disease) associated with a novel mutation in CTSD","volume":"263","author":"Doccini","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.bbadis.2020.165772_bb0525","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1212\/WNL.0000000000000981","article-title":"Cathepsin D deficiency causes juvenile-onset ataxia and distinctive muscle pathology","volume":"83","author":"Hersheson","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.bbadis.2020.165772_bb0530","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/nature05016","article-title":"Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17","volume":"442","author":"Baker","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2020.165772_bb0535","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/nature05017","article-title":"Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21","volume":"442","author":"Cruts","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2020.165772_bb0540","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1523\/JNEUROSCI.3081-17.2018","article-title":"Progranulin gene therapy improves lysosomal dysfunction and microglial pathology associated with frontotemporal dementia and neuronal ceroid lipofuscinosis","volume":"38","author":"Arrant","year":"2018","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbadis.2020.165772_bb0545","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.ymthe.2018.11.013","article-title":"AAV-mediated progranulin delivery to a mouse model of progranulin deficiency causes T cell-mediated toxicity","volume":"27","author":"Amado","year":"2019","journal-title":"Mol. Ther."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443920301174?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443920301174?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T04:56:14Z","timestamp":1760417774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443920301174"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":109,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0925443920301174"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2020.165772","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experimental gene therapies for the NCLs","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2020.165772","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"165772"}}